Alendronate
Unchecked
Alendronate
Fosamax, Binosto
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Osteoporosis treatment (postmenopausal, male, glucocorticoid-induced)0, Osteoporosis prevention0, Paget's disease of bone0
Pharmacy
Starting dose
Treatment 70 mg PO once weekly (or 10 mg daily); prevention 35 mg weekly (or 5 mg daily); always taken first thing in the morning with a full glass of water, remaining upright for 30 minutes
Preparations
5, 10, 35, 40, 70 mg tablets; 70 mg/75 mL oral solution; 70 mg effervescent (Binosto)
US FDA Max
70 mg/week treatment; 40 mg/d for 6 months in Paget's
Pharmacology
Routes
Oral
Onset
Bone marker reduction within weeks; BMD improvement at 1-3 years; fracture-risk reduction documented at 3-5 years
Duration
Weeks; bone retention years
Half-life
Plasma ~3 hours; bone half-life ~10 years[1]
Bioavailability
<1% (oral; further reduced by food, calcium, iron, antacids; hence the strict fasting/upright dosing rules)[1]
Pregnancy
Long-term skeletal retention is a concern given the unknown effect on developing fetal bone; generally avoided.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Alendronate is a nitrogen-containing bisphosphonate that adsorbs to hydroxyapatite at sites of active bone remodeling, is taken up by osteoclasts during resorption, and inhibits farnesyl pyrophosphate synthase in the mevalonate pathway; loss of prenylation impairs osteoclast cytoskeleton and ruffled border, slowing bone resorption and shifting net remodeling toward formation.0 Drug-holiday concept (3-5 years on, 1-2 years off) emerged from FLEX and long-term safety data balancing fracture protection against atypical femoral fracture and osteonecrosis of the jaw signals[1].
References
[edit | edit source]- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Fosamax (alendronate sodium), Merck, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020560s045lbl.pdf